bluuebunny/crossref_metadata_2025_split huggingface dataset:
B cell antigen receptor cross-linking triggers rapid protein kinase C independent activation of p21ras1.
Authors: Harwood A E , Cambier J C 
Published: January 2023

Abstract
Membrane Ig (mIg) functions in binding and internalization of Ag for subsequent processing and presentation to T cells, as well as in transmembrane transduction of signals that lead to cell activation, proliferation, and differentiation. Tyrosine kinase activation and subsequent phosphatidylinositol hydrolysis and Ca2+ mobilization are clearly important intermediary events in receptor-mediated B cell activation. However, many details of the cellular signal transduction pathways utilized by this receptor are not resolved. Recent studies that demonstrated co-capping of mIg and the proto-oncoprotein p21ras suggested that this low m.w. GTP-binding protein may function in mIg-mediated signal transduction. p21ras has been implicated in some but not all protein tyrosine kinase/phospholipase C involving signaling pathways. To explore the potential role of p21ras in B cell Ag receptor-mediated signaling, we assessed the effect of Ag receptor ligation on the proportion of p21ras in the active GTP-bound state. We present evidence that p21ras is activated by mIgM and mIgG cross-linking by anti-receptor antibodies as well as by Ag. Depending upon the stimulus employed, this response is detectable within 1 min and occurs with similar kinetics as inductive protein tyrosine phosphorylation and Ca2+ mobilization. Ag dose dependence of this response is similar to that of inductive protein tyrosine phosphorylation. In these cells p21ras is also activated by PMA suggesting that p21ras activation after receptor cross-linking may be mediated by an effector molecule that functions downstream from protein kinase C (PKC). However, the kinetics of p21ras activation after mIg cross-linking are inconsistent with the possibility that PKC functions as the sole mediator of p21ras activation in this system. Finally, under conditions in which the PKC inhibitor calphostin C blocks PMA-induced p21ras activation, it does not inhibit Ag-induced p21ras activation. These data suggest that PKC effector mechanisms play a negligible role in p21ras activation during mIg-mediated signaling.
Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration.
Authors: Jinquan T , Larsen C G , Gesser B , Matsushima K , Thestrup-Pedersen K 
Published: January 2023

Abstract
Human IL-10 (hIL-10) is a newly described cytokine that was originally identified as a cytokine synthesis inhibitory factor regulating the production of several pro-inflammatory cytokines such as IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF-alpha, and IFN-gamma. Additionally, hIL-10 also inhibits the macrophage-dependent proliferative response of CD4+ T lymphocytes to Ag stimulation, and it down-regulates the constitutive class II MHC expression on human monocytes. We report hIL-10 to be a potent and specific chemotaxin for human T lymphocytes with optimum activity in the range between 10 and 100 U/ml. Checkerboard analysis shows the activity to be chemotactic and not chemokinetic. The chemotactic activity is directed toward CD8+ T lymphocytes and not towards CD(4+)-enriched cells. Also, hIL-10 lacks chemotactic activity toward human monocytes or neutrophil granulocytes. Further, we found that hIL-10 inhibits the chemotactic response of CD4+, but not CD8+, T cells toward IL-8. Because hIL-10 can be produced by several cells including CD4+ T cells of the Th2 type, our results suggest that hIL-10 participates in a complex regulatory circuit between CD4+ and CD8+ T cells with implications for the control of lymphocyte-mediated inflammatory responses.
Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Authors: Mokyr M B , Rubin M , Newell K A , Prokhorova A , Bluestone J A 
Published: January 2023

Abstract
We have previously shown that the curative efficacy of low dose melphalan (L-phenylalanine mustard; L-PAM) for mice bearing a large s.c. MOPC-315 tumor requires the participation of CD8+ (but not CD4+) T cell-dependent antitumor immunity. Here we show that CD8+ T cells obtained from regressing tumors on day 4 or 5 after low dose L-PAM therapy of MOPC-315 tumor bearers (L-PAM TuB mice) display a preferential enhancement in the utilization of the TCR-V beta 8.3 gene segment as compared to CD8+ T cells from normal lymph nodes. Treatment of L-PAM TuB mice with mAb F23.1, which leads to the depletion of V beta 8.3+ cells, as well as V beta 8.1 and 8.2+ cells, led to a significant reduction in the ability of their tumor-infiltrating lymphocytes as well as their spleen cells to lyse MOPC-315 tumor cells in vitro in a short term assay. In addition, the mAb F23.1 treatment almost completely abrogated the lytic activity of the tumor-infiltrating lymphocytes against another syngeneic, antigenically related plasmacytoma (the MOPC-104E). Moreover, the mAb F23.1 treatment significantly reduced the curative effectiveness of low dose L-PAM for mice bearing a large MOPC-315 tumor. In contrast, mAb KJ16 treatment, which leads to the depletion of V beta 8.1 and 8.2+ cells (but not V beta 8.3+ cells), did not reduce significantly the curative effectiveness of low dose L-PAM for such MOPC-315 tumor bearers. Thus, V beta 8.3+ T cells are important for the curative effectiveness of low dose L-PAM therapy for MOPC-315 tumor bearers, and it is conceivable that the V beta 8.3+ cells mediate their effect (at least in part) by contributing to the acquisition of CTL activity against plasmacytoma-shared Ag.
Cross-linking of the carcinoembryonic antigen-like glycoproteins CD66 and CD67 induces neutrophil aggregation.
Authors: Kuijpers T W , van der Schoot C E , Hoogerwerf M , Roos D 
Published: January 2023

Abstract
The carcinoembryonic Ag (CEA)-like glycoproteins present on human granulocytes have been designated non-specific cross-reacting Ag (NCA). We have recently demonstrated that granulocyte-specific CD66 and CD67 mAb recognize the three originally described NCA. CD66 binds to NCA-160 and NCA-90, whereas CD67 only recognizes NCA-95. As we have shown previously, NCA-160 and NCA-90 present sialylated Lewis-X oligosaccharide Ag (SLex) in a functional way, i.e., these Ag function as (one of many possible) molecules involved in neutrophil binding to the adhesion molecule E-selectin expressed on activated endothelial cells. In this study, we found that a polyclonal anti-CEA antiserum, either as intact Ig or as F(ab')2 fragments, induced neutrophil aggregation. This aggregation response was blocked by CD18 mAb. Neutrophils from a patient severely affected by paroxysmal nocturnal hemoglobinuria completely lacked expression of NCA-95 and NCA-90. The patient's neutrophils repeatedly showed no aggregation on addition of the anti-CEA antiserum. Thus, the presence of the phosphatidylinositol-linked NCA-95/90 seems to be essential for NCA-induced neutrophil activation. Our data indicate that NCA molecules on neutrophils may function via binding to E-selection or an as yet unknown ligand (as mimicked here by an antiserum) and subsequently induce CD18-dependent adhesive properties.
Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys.
Authors: Yasutomi Y , Palker T J , Gardner M B , Haynes B F , Letvin N L 
Published: January 2023

Abstract
In view of the importance of cell-associated virus in AIDS virus transmission, an HIV vaccine should be able to induce a virus-specific CTL response. Traditional subunit vaccines have not elicited virus-specific CD8+ MHC class I-restricted CTL. We have used the simian immunodeficiency virus of macaques (SIVmac)/rhesus monkey model to explore the use of CTL epitope peptide-helper peptide conjugates for the vaccine elicitation of AIDS virus-specific CTL. We found that both the CTL epitope peptide-helper peptide conjugate and the CTL epitope peptide alone, when delivered in an emulsion with IFA, induced CTL epitope-specific CD8+ MHC class I-restricted CTL. These effector cells recognized processed viral protein and were readily cloned from PBL of the immunized monkeys. Moreover, the cloned effector cells inhibited SIVmac replication in PBL. Immunization with the CTL epitope peptide used in this study also elicited a CD4+ PBL proliferative response, suggesting that the peptide also contained a helper epitope. These studies provide further evidence for the potential usefulness of peptide-based AIDS virus vaccines.
Characteristics of heterologous beta 2-m exchange into H-2Db at the cell surface.
Authors: Luscher M A , Newton B L , Barber B H 
Published: January 2023

Abstract
W6/32 is a monomorphic anti-HLA class I Ab that cross-reacts with the product of the exchange of murine beta 2-microglobulin (beta 2-m) with human or bovine beta 2-m on H-2 Db. Using W6/32 we have developed a simple and rapid flow cytometric method to measure the beta 2-m exchange kinetics for Db at the surface of intact H-2b cell lines. We find that 10 to 25% of the Db heavy chains exchange bound beta 2-m for soluble beta 2-m with a t1/2 of 10 to 15 min. The kinetics of the exchange are consistent with a mechanism that includes a free heavy chain intermediate on the reaction coordinate. The remainder of Db molecules appear to be refractory to beta 2-m exchange even after long-term culture with an exogenous source of beta 2-m. The exchange process proceeds at a similar rate on wild-type cells that bear a diverse complement of autologous peptides on their class I molecules, and on mutant RMA-S cells having class I molecules primarily occupied with a single, defined, high affinity synthetic peptide Ag. The t1/2 for dissociation of a radiolabeled analogue of a high affinity naturally presented peptide Ag is 10 h or more, implying that the free heavy chain intermediate in the beta 2-m exchange mechanism retains bound peptides. Further, we find that synthetic peptide Ags added to non-mutant cells bind both to class I molecules that subsequently exchange bound beta 2-m, and to molecules that retain endogenous beta 2-m.
Inhibition by insoluble immune complexes of both capacitative Ca2+ entry and Ca2+ mobilization by chemotactic agonists in human neutrophils.
Authors: Montero M , Steil A A , Sanchez Crespo M , Garcia-Sancho J , Alvarez J 
Published: January 2023

Abstract
Insoluble immune complexes (IIC) stimulate human neutrophils by binding to their FcR. It is known that they are able to release Ca2+ from intracellular stores but they induce little Ca2+ entry from the extracellular medium, a dissociation that cannot be explained within the framework of the capacitative model for Ca2+ entry, which is well established for these cells. We show here that IIC induce a strong and long-lasting inhibition of the Ca2+ pathway activated by emptying the Ca2+ stores (capacitative Ca2+ entry), which develops simultaneously with the activation of Ca2+ release from intracellular stores. This inhibition strongly resembles that previously described effected by FMLP and by phorbol dibutyrate, which seems to be mediated by phosphorylation. Inhibition by IIC, however, differs from that induced by FMLP and phorboldibutyrate in its lack of sensitivity to cytosolic-free calcium concentration and in its different sensitivity to the protein kinase inhibitors staurosporin and chelerythrine. It was also insensitive to the protein tyrosine kinase inhibitors genistein and herbimycin A. We also show that IIC inhibit Ca2+ mobilization induced by other agonists and that this inhibition is potentiated by the protein phosphatase inhibitor calyculin A. Our results therefore suggest that binding of IIC to the FcR activates a protein phosphorylation mechanism leading to a long-lasting inhibition of both capacitative Ca2+ entry and Ca2+ mobilization induced by other agonists such as FMLP, platelet-activating factor, or leukotriene B4.
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis.
Authors: Romani L , Mencacci A , Tonnetti L , Spaccapelo R , Cenci E , Puccetti P , Wolf S F , Bistoni F 
Published: January 2023

Abstract
In murine models of systemic candidiasis, healing and nonhealing patterns of disease are associated with preferential expansion of Th1 and Th2 cells, respectively. As previous studies have shown IL-12 to be expressed transcriptionally in healer mice and to be required for Th1 development in vitro, this cytokine might play a role in Candida-driven Th1 cell differentiation in vivo. In the present study, IL-12-neutralizing Abs or recombinant IL-12 were administered to mice with healing or progressive candidiasis, respectively, and the animals were monitored for mortality, resistance to reinfection, serum levels of specific Abs, and IFN-gamma, IL-4, and IL-10 message/protein expression by CD4+ cells. In self-limiting infection by a yeast vaccine strain, neutralization of IL-12 ablated development of acquired anticandidal resistance and led to appearance of Candida-specific IgE and IL-4-producing cells. In mice with progressive systemic disease as well as in a mucosal infection model, administration of IL-12 did not result in therapeutic activity under conditions of yeast infection that would instead be resolved by serologic ablation of IL-4 or IL-10. Yet, in systemically infected mice cured by anti-IL-4 or anti-IL-10 therapy, the emergence of a Th1 response correlated with the detection of high levels of circulating IL-12 and splenic IL-12 transcripts. Although exogenous IL-12 may not be sufficient for Th conversion in the presence of an overwhelming IL-4/IL-10 response, endogenous production of IL-12 may be both required and prognostic for Th1 differentiation in vivo.
Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities.
Authors: Stepkowski S M , Tu Y , Condon T P , Bennett C F 
Published: January 2023

Abstract
Intercellular adhesion molecule-1 (ICAM-1) binds circulating leukocytes through interactions with beta 2 integrins, LFA-1, and macrophage Ag-1. The phosphorothioate antisense oligodeoxynucleotide, IP-3082, specific for ICAM-1 mRNA inhibited ICAM-1, but not vascular cell adhesion molecule-1, mRNA induction and expression of ICAM-1 molecules by mouse endothelioma cells. Scrambled control oligonucleotides were ineffective. Untreated C3H (H-2k) mice rejected C57BL/10 (H-2b) heart allografts with a mean survival time of 7.7 +/- 1.4 days. Administration i.v. of IP-3082 by a 7-day osmotic pump prolonged the survival of heart allografts in a dose-dependent fashion: 1.25 mg/kg, to 11 +/- 0 days; 2.5 mg/kg, to 12 +/- 2.7 days; 5 mg/kg, to 14.1 +/- 2.7 days; and 10 mg/kg, to 15.3 +/- 5.8 days (all p &lt; 0.01). Control IP-1082 (10 mg/kg) was ineffective (7 +/- 0.8 days). Although 7-day anti-LFA-1 mAb (50 micrograms/day; i.p.) prolonged allograft survival to 14.1 +/- 2.7 days, the addition of IP-3082 (5.0 mg/kg x 7 days) induced donor-specific transplantation tolerance (&gt; 150 days). Furthermore, IP-3082 (5 mg/kg x 7 days) acted synergistically with antilymphocyte serum, rapamycin, and brequinar, but not cyclosporin A: a single antilymphocyte serum (0.2 ml) i.p. injection alone prolonged graft survival to 10 +/- 0.5 days (p &lt; 0.01) and in combination with IP-3082 (5 mg/kg), to 32.2 +/- 8.3 days (p &lt; 0.001); rapamycin (0.1 mg/kg x 7 days; i.v.) alone prolonged survival to 13 +/- 7.5 days (p &lt; 0.01), and with IP-3082, to 32.4 +/- 8.9 days (p &lt; 0.03); brequinar (0.5 mg/kg x 7 days; oral gavage) alone to 12 +/- 2.4 days (p &lt; 0.05), and with IP-3082 (5 mg/kg), to 38.8 +/- 30.2 days (p &lt; 0.01); in contrast, cyclosporin A (5 mg/kg x 7 days; i.v.) alone produced graft survival of 9.8 +/- 1.3 days (p &lt; 0.1 and in combination with IP-3082 (5 mg/kg), produced survival of 7.8 +/- 3.5 days (NS). Thus, antisense oligonucleotides may proffer a selective gene-targeted immunosuppressive therapy for organ transplantation.
Poly ADP-ribosylation of a 90-kDa protein is involved in TNF-alpha-mediated cytotoxicity.
Authors: Agarwal S , Piesco N P 
Published: January 2023

Abstract
Nicotinamide and 3-aminobenzamide prevent TNF-alpha-mediated cytotoxicity, indicating that ADP-ribosylation plays a crucial role in this reaction. We have studied the role of ADP-ribosylation during TNF-alpha action in TNF-alpha-sensitive and TNF-alpha-resistant cells. Treatment of 3T3 cells with TNF-alpha, in the presence of [adenylate-32P]NAD followed by SDS-PAGE, revealed the involvement of specific ADP-ribosylation of a 90-kDa protein in TNF-alpha-mediated cytotoxicity. The stability of the ADP-ribosyl linkage on the 90 kDa protein in 100 mM 2-(N-cyclohexylamino)ethanesulfonic acid at pH 9.0 confirmed that ADP-ribosylation of the 90 kDa protein was mediated by an enzymatic reaction. Analysis of ADP-ribose residues by phosphodiesterase hydrolysis showed that the 90-kDa protein was modified by poly ADP-ribosylation. Poly ADP-ribosylation of the 90-kDa protein concomitant with cytotoxicity was observed in all TNF-alpha-sensitive but not TNF-alpha-resistant cells. Inhibition of ADP-ribosylation of the 90-kDa protein by benzamide but not by benzoic acid abrogated cytotoxicity, which further suggested that the poly-ADP-ribosylation of the 90-kDa protein is causally related to TNF-alpha-induced cell death. Our results demonstrate that TNF-alpha modifies a specific protein by poly-ADP-ribosylation during its action. Furthermore, ADP-ribosylation of specific proteins may be yet another mechanism regulating protein function during cellular metabolism.
In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies.
Authors: Bemelmans M H , Abramowicz D , Gouma D J , Goldman M , Buurman W A 
Published: January 2023

Abstract
Injection of anti-CD3 is accompanied by an increase in systemic TNF, a mediator of the physiologic changes induced by anti-CD3 injection. Various mechanisms have been reported to be responsible for TNF inactivation and clearance. Recently, it has become evident that circulating soluble TNFRs (P55 and P75), which are known to increase in response to TNF inducers such as LPS, represent a natural protection mechanism against circulating TNF. Here we show that triggering the TCR by anti-CD3 injection results in a strong induction of both systemic TNF and soluble TNFR release. Maximal levels of TNF were reached after 2 h (10 ng/ml). Maximum levels of P55 (450 pg/ml) were reached between 0.5 and 8 h, whereas the highest levels of P75 were reached after 2 h (28 ng/ml). Because TNF and IFN-gamma are supposed to be involved in the pathophysiology of the anti-CD3 response, we investigated the influence of in vivo neutralization of TNF and IFN-gamma. Injection of mAb to TNF and IFN-gamma significantly reduced systemic TNF levels and both soluble TNFR levels. Two inhibitors of anti-CD3 induced TNF release; steroids and pentoxifylline both reduced TNF levels and P75 levels without affecting P55 levels. The results show that T cell activation induces both systemic TNF release and release of both soluble TNFRs. Although TNF and IFN-gamma are involved in this mechanism, their role does not seem to be crucial.
IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells.
Authors: Wang P , Wu P , Siegel M I , Egan R W , Billah M M 
Published: January 2023

Abstract
Upon addition of LPS to human PBMCs, IL-1 beta, IL-6, and TNF-alpha were released in the culture media in a time-dependent manner. Cytokine release began 2 h after LPS addition and maximal release of all three cytokines was observed between 6 and 8 h. Northern analysis revealed that, for each cytokine, mRNA accumulation preceded protein release. When added either 2 h before or at the same time as LPS, IL-10 inhibited both the cytokine release and mRNA accumulation almost completely. Similar inhibition was observed when IL-10 was added 2 h after LPS, a time point that coincided with the onset of the rapid burst of cytokine mRNA accumulation. The inhibitory activity of IL-10 was abrogated by cycloheximide, suggesting an involvement of newly synthesized proteins in IL-10 action. By using nuclear run-on transcription assays, we have found that IL-10 inhibited transcription of all three cytokine genes in LPS-stimulated PBMCs. In contrast, IL-10 moderately enhanced degradation of IL-6 mRNA, but not of mRNAs for IL-1 beta and TNF-alpha. Thus, the present study provides the first evidence that, in human PBMCs, IL-10 inhibits cytokine synthesis by acting mainly at the level of cytokine gene transcription.
The role of self peptides in the allogeneic cross-reactivity of CTLs.
Authors: Kuzushima K , Sun R , van Bleek G M , Vegh Z , Nathenson S G 
Published: January 2023

Abstract
This study presents data relevant to understanding the molecular and structural basis for the cross-reactivity of many CTLs on multiple MHC targets. Five anti-H-2Kb alloreactive CTL clones derived from B6.C-H-2bm1 (bm1), B6.C-H-2bm8 (bm8), and B6.C-H-2bm11 (bm11) mice and a Sendai virus-specific H-2Kb-restricted CTL clone were studied. Self peptides extracted from Kb molecules were fractionated by HPLC and tested for their ability to be recognized on RMA/s (H-2b) cells by those clones. For each alloreactive clone, a single dominant peptide peak was found to sensitize target cells. In addition to recognizing peptides presented by the Kb molecule, the five alloreactive clones and the one Sendai virus-specific clone all showed cross-reactivities on a panel of Kbm mutant cells in a peptide-dependent manner. Two CTL clones, one alloreactive and one virus specific, cross-recognized Kbm targets by each responding to a unique self peptide in the context of the mutant MHC molecules. Our data underscore the prevalent idea that TCR-alpha beta have an inherent structural capability to react with several peptide/MHC structural patterns other than the original peptide/MHC pattern that might have been used to select that TCR. The high incidence of cross-reactivity seems to reflect a feature of the mechanism of positive selection in the thymus and the need for T cells in the repertoire to have an expanded capability for responding to a wide variety of foreign Ags.
Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes.
Authors: Geng Y , Blanco F J , Cornelisson M , Lotz M 
Published: January 2023

Abstract
This study analyzes cyclooxygenase II (COX-2) gene expression, protein synthesis, and PGE2 release in normal human articular chondrocytes. Stimulation of chondrocytes in primary culture resulted in a dose-dependent induction of COX-2 mRNA in response to IL-1 with an ED50 between 0.1 and 1 ng/ml. COX-2 mRNA was detectable after 2 h, reached high levels at 6 h, and showed a remarkably long duration of expression for at least 72 h. Analysis of other extracellular stimuli showed that COX-2 mRNA was inducible by other cytokines including TNF-alpha, IL-6, and LIF and by bacterial LPS. Dexamethasone completely inhibited IL-1-induced COX-2 mRNA expression. Analysis of signaling pathways showed that PMA and calcium ionophore A23187, but not dibutyryl cAMP, induced COX-2 mRNA. The combination of IL-1 and A23187 resulted in synergistic increases. IL-1 effects were not reduced by the protein kinase C inhibitor staurosporine or by the protein kinase A inhibitor H89 but blocked by the protein tyrosine kinase inhibitor herbimycin A. COX-2 protein was detected at 71 kDa by Western blotting in IL-1-stimulated, and to almost similar levels in A23187-treated, cells. Flow cytometric analysis showed that after IL-1 stimulation 78% of the chondrocytes expressed COX-2 protein. The patterns of COX-2 protein expression and the levels of PGE2 release correlated with the effects of the different stimuli and inhibitors on mRNA expression.